Abstract
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder leading to dementia. A major neuropathological hallmark of AD is the deposition of amyloid-β protein (Aβ) in the form of neuritic plaques. Aβ is formed by the sequential cleavage of amyloid-β precursor protein (APP) by β- and γ -secretase. It was recently suggested that TMP21 is a novel member of the γ-secretase complex which negatively regulates APP cleavage at the γ-site, but does not affect cleavage of APP or Notch at the -site . In vitro knockdown of TMP21 increases Aβ production and AD patients have less TMP21 expressed in their brains, suggesting that a deficiency in TMP21 may exacerbate AD pathology. TMP21 is most commonly known for its role in vesicle trafficking. Here we present the most recent research on TMP21 in relation to AD, including TMP21’s roles in the modulation of γ-secretase activity and protein trafficking.
Keywords: TM21, trafficking, Alzheimer, dementia, hyperphosphorylated tau, ß-secretase, Protease Inhibitor, cytosis, cytoskeletal track
Current Alzheimer Research
Title:The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease
Volume: 9 Issue: 4
Author(s): Kelley Bromley-Brits, Weihong Song
Affiliation:
Keywords: TM21, trafficking, Alzheimer, dementia, hyperphosphorylated tau, ß-secretase, Protease Inhibitor, cytosis, cytoskeletal track
Abstract: Alzheimer’s Disease (AD) is the most common neurodegenerative disorder leading to dementia. A major neuropathological hallmark of AD is the deposition of amyloid-β protein (Aβ) in the form of neuritic plaques. Aβ is formed by the sequential cleavage of amyloid-β precursor protein (APP) by β- and γ -secretase. It was recently suggested that TMP21 is a novel member of the γ-secretase complex which negatively regulates APP cleavage at the γ-site, but does not affect cleavage of APP or Notch at the -site . In vitro knockdown of TMP21 increases Aβ production and AD patients have less TMP21 expressed in their brains, suggesting that a deficiency in TMP21 may exacerbate AD pathology. TMP21 is most commonly known for its role in vesicle trafficking. Here we present the most recent research on TMP21 in relation to AD, including TMP21’s roles in the modulation of γ-secretase activity and protein trafficking.
Export Options
About this article
Cite this article as:
Kelley Bromley-Brits, Weihong Song , The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease, Current Alzheimer Research 2012; 9 (4) . https://dx.doi.org/10.2174/156720512800492521
DOI https://dx.doi.org/10.2174/156720512800492521 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibrin Clot Properties and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Current Drug Targets Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine The Catalytic Core of γ-Secretase: Presenilin Revisited
Current Alzheimer Research Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease
Current Medical Imaging Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease
Current Alzheimer Research Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process
Letters in Drug Design & Discovery